Changes in plasma d-serine, l-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment

Neuroscience Letters

Volumn 582, Issue , 2014, Pages 93-98

  Yamamori, Hidenaga ^a   Hashimoto, Ryota ^a,b   Fujita, Yuko ^c   Numata, Shusuke ^d   Yasuda, Yuka ^a   Fujimoto, Michiko ^a   Ohi, Kazutaka ^a   Umeda Yano, Satomi ^a   Ito, Akira ^a   Ohmori, Tetsuro ^d   Hashimoto, Kenji ^c   Takeda, Masatoshi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Clozapine; Glycine; Plasma; Serine; Treatment resistant schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DEXTRO SERINE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; SERINE; NEUROLEPTIC AGENT;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HUMAN; MALE; OUTCOME ASSESSMENT; SCHIZOPHRENIA; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESISTANT SCHIZOPHRENIA; BLOOD; CASE CONTROL STUDY; CHEMISTRY; MIDDLE AGED; STEREOISOMERISM; TREATMENT FAILURE;

ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CLOZAPINE; FEMALE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SERINE; STEREOISOMERISM; TREATMENT FAILURE;

EID: 84907406788     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.08.052     Document Type: Article

References (26)

1. Baruah S., Waziri R., Hegwood T.S., Mallis L.M. Plasma serine in schizophrenics and controls measured by gas chromatography-mass spectrometry. Psychiatry Res. 1991, 37:261-270.
2. Bendikov I., Nadri C., Amar S., Panizzutti R., De Miranda J., Wolosker H., Agam G. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr. Res. 2007, 90:41-51.
3. Brouwer A., Luykx J.J., van Boxmeer L., Bakker S.C., Kahn R.S. NMDA-receptor coagonists in serum, plasma, and cerebrospinal fluid of schizophrenia patients: a meta-analysis of case-control studies. Neurosci. Biobehav. Rev. 2013, 37:1587-1596.
4. Calcia M.A., Madeira C., Alheira F.V., Silva T.C., Tannos F.M., Vargas-Lopes C., Goldenstein N., Brasil M.A., Ferreira S.T., Panizzutti R. Plasma levels of d-serine in Brazilian individuals with schizophrenia. Schizophr. Res. 2012, 142:83-87.
5. D'Souza D.C., Gil R., Cassello K., Morrissey K., Abi-Saab D., White J., Sturwold R., Bennett A., Karper L.P., Zuzarte E., Charney D.S., Krystal J.H. IV glycine and oral d-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol. Psychiatry 2000, 47:450-462.
6. De Luca V., Viggiano E., Messina G., Viggiano A., Borlido C., Viggiano A., Monda M. Peripheral amino acid levels in schizophrenia and antipsychotic treatment. Psychiatry Investig. 2008, 5:203-208.
7. Farber N.B., Newcomer J.W., Olney J.W. Glycine agonists: what can they teach us about schizophrenia?. Arch. Gen. Psychiatry 1999, 56:13-17.
8. Fekkes D., Pepplinkhuizen L., Verheij R., Bruinvels J. Abnormal plasma levels of serine, methionine, and taurine in transient acute polymorphic psychosis. Psychiatry Res. 1994, 51:11-18.
9. Fukushima T., Kawai J., Imai K., Toyo'oka T. Simultaneous determination of d- and l-serine in rat brain microdialysis sample using a column-switching HPLC with fluorimetric detection. Biomed. Chromatogr. 2004, 18:813-819.
10. Hashimoto A., Nishikawa T., Hayashi T., Fujii N., Harada K., Oka T., Takahashi K. The presence of free d-serine in rat brain. FEBS Lett. 1992, 296:33-36.
11. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindstrom L.H., Iyo M. Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:767-769.
12. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., Iyo M. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003, 60:572-576.
13. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 2007, 62:1310-1316.
14. Hons J., Vasatova M., Cermakova E., Doubek P., Libiger J. Different serine and glycine metabolism in patients with schizophrenia receiving clozapine. J. Psychiatr. Res. 2012, 46:811-818.
15. Hons J., Zirko R., Ulrychova M., Cermakova E., Doubek P., Libiger J. Glycine serum level in schizophrenia: relation to negative symptoms. Psychiatry Res. 2010, 176:103-108.
16. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
17. Korpi E.R., Kleinman J.E., Goodman S.I., Wyatt R.J. Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients. Psychiatry Res. 1987, 22:291-301.
18. Macciardi F., Lucca A., Catalano M., Marino C., Zanardi R., Smeraldi E. Amino acid patterns in schizophrenia: some new findings. Psychiatry Res. 1990, 32:63-70.
19. Matsui T., Sekiguchi M., Hashimoto A., Tomita U., Nishikawa T., Wada K. Functional comparison of d-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration. J. Neurochem. 1995, 65:454-458.
20. Neeman G., Blanaru M., Bloch B., Kremer I., Ermilov M., Javitt D.C., Heresco-Levy U. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am. J. Psychiatry 2005, 162:1738-1740.
21. Ohnuma T., Arai H. Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:29-39.
22. Ohnuma T., Sakai Y., Maeshima H., Hatano T., Hanzawa R., Abe S., Kida S., Shibata N., Suzuki T., Arai H. Changes in plasma glycine, l-serine, and d-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1905-1912.
23. Perry T.L. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci. Lett. 1982, 28:81-85.
24. Sumiyoshi T., Anil A.E., Jin D., Jayathilake K., Lee M., Meltzer H.Y. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int. J. Neuropsychopharmacol. 2004, 7:1-8.
25. Yamada K., Ohnishi T., Hashimoto K., Ohba H., Iwayama-Shigeno Y., Toyoshima M., Okuno A., Takao H., Toyota T., Minabe Y., Nakamura K., Shimizu E., Itokawa M., Mori N., Iyo M., Yoshikawa T. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and d-serine levels. Biol. Psychiatry 2005, 57:1493-1503.
26. Yamamori H., Hashimoto R., Ishima T., Kishi F., Yasuda Y., Ohi K., Fujimoto M., Umeda-Yano S., Ito A., Hashimoto K., Takeda M. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci. Lett. 2013, 556:37-41.